Incyte reports PFS data for IDO1 combo to treat melanoma

Incyte Corp. (NASDAQ:INCY) and Merck & Co. Inc. (NYSE:MRK) reported updated data from a cohort of advanced melanoma patients in the ongoing Phase I/II ECHO-202/KEYNOTE-037 study of epacadostat (INCB24360) in combination with PD-1 inhibitor Keytruda pembrolizumab. Epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Data were presented at the European Society for Medical Oncology meeting in Madrid.

Among 63 evaluable patients, the combination led to a median progression-free survival (PFS) of 12.4 months. PFS rates at six, 12 and 18 months were 65%, 52% and 49%, respectively. ...